Invitation to Alligator Bioscience’s interim report call on 22 October 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...
Alligator Bioscience appoints Johan Giléus as CEO – Søren Bregenholt to step down at year-end
Johan Giléus, currently CFO, has been appointed CEO effective 1 January 2027 Søren Bregenholt will remain CEO until 31 Decembe ...
Alligator Bioscience carries out a directed issue of warrants to Fenja Capital in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces preliminary outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience publishes prospectus in connection with rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Bulletin from the extraordinary general meeting in Alligator Bioscience AB
Today, on 26 August 2026, an extraordinary general meeting was held in Alligator Bioscience AB. A summary of the adopted resolutions follows ...
Alligator Bioscience AB reports financial results for the period 1 January – 30 June 2026 and provides a business update
Strategic refocus: After the quarter, Alligator discontinued all further independent development of mitazalimab and refocused on preserving ...
Invitation to Alligator Bioscience’s earnings call on 26 August 2026
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company whose principal asset is a financial interest i ...